

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 September 2021 (16.09.2021)



(10) International Publication Number
WO 2021/180984 A1

(51) International Patent Classification:

C12N 5/071 (2010.01) A01N 1/02 (2006.01)
A61K 35/407 (2015.01)

(21) International Application Number:

PCT/EP2021/056574

(22) International Filing Date:

15 March 2021 (15.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20305267.5 13 March 2020 (13.03.2020) EP

(71) Applicants: **GOLIVER THERAPEUTICS** [FR/FR]; 8 quai Moncoussu, BP 70721, 44007 Nantes Cedex 1 (FR). **UNIVERSITÉ DE NANTES** [FR/FR]; 1 quai de Tourville, 44000 Nantes (FR). **INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)** [FR/FR]; 101 rue de Tolbiac, 75654 Paris Cedex 13 (FR).

(72) Inventors: **NGUYEN, Tuan Huy**; 15 rue des Friches, 44300 Nantes (FR). **FOURRIER, Angélique**; 2 rue Arthur Rimbaud, Clos des Arts, Bâtiment F, 44880 Sautron (FR). **RISPAL, Raphaël**; 22 avenue de la Libération, 44400 Rezé (FR). **DELBOS, Frédéric**; 51 bis rue du Largeau, 44230 Saint-Sébastien-sur-Loire (FR).

(74) Agent: **ICOSA**; 83 avenue Denfert-Rochereau, 75014 Paris (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))



WO 2021/180984 A1

(54) Title: HEPATIC STEM-LIKE CELLS FOR THE TREATMENT AND/OR THE PREVENTION OF FULMINANT LIVER DISORDERS

(57) Abstract: The present invention relates to a population of cells comprising hepatic stem-like cells and therapeutic use thereof, for the treatment and the prevention of fulminant liver disorders. The hepatic stem-like cells according to the invention may be safely and reproducibly generated from pluripotent stem cells. In addition, although the hepatic stem-like cells according to the invention do not display the phenotype of physiologically mature hepatic cells, as they are lacking the albumin expression marker (ALB-), they may still be transplanted in a diseased liver with acute failure, rescue the diseased liver and promote liver regeneration. Moreover, various protocols of preparation of hepatic stem-like cells according to the invention may be implemented, all resulting in high quality and high yield of production. Finally, the hepatic stem-like cells according to the invention may be cryopreserved and may also be prepared as spheroid particles.